Interventional Cardiology Devices – Market Insights – Europe

The European IC device market is seeing a steady uptake of several technologies post the pandemic era, these technologies have supported the IC device space and will continue to do so over the forecast period. In addition, premium priced advanced technologies are poised to enter the market, which could potentially change the existing treatment algorithms and disrupting the established category leaders.

This Medtech 360 Report provides comprehensive data and analysis on the state of the market for IC devices in Europe from 2019 through 2033.

The coronary stent segment is a highly competitive space, with the leading companies continuing to launch updates to their flagship devices.

What are the market share dynamics among the three major competitors in the highly lucrative DES device market?

What competitive strategies are the major companies implementing to gain market share in this market, and how are ASPs being impacted by the strong competition?

How will the market landscape change over the next few years for coronary stents upon adoption of BRS? What is the developmental pipeline for the next generation of BRS?

The introduction of intravascular lithotripsy has revolutionized the treatment of calcified coronary lesions and vessel preparation prior to stenting.

How has the commercialization of coronary lithotripsy impacted the use of other products used in the interventional cardiology space?

How is reimbursement changing for coronary lithotripsy, and how will this affect adoption of this technology?

New technologies are expected to receive approval in the near future and change the way complex PCIs are diagnosed and treated.

What is the impact of the latest generation of alternative coronary physiology modalities such as resting index or imaging-based FFRangio and FFRCT on the patient and procedure in cardiac catheterization labs?

How will the emergence of alternative FFR modalities affect the FFR pressure guidewire market?

What is the expected impact of emerging balloon-based technologies such as DCBs?

How are new clinical trials impacting IC device segments, procedures, competitors, and products?

Table of contents